Highlights Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-15 EDT			5-day change	1st Jan Change
0.808 ^USD	-2.42%		-21.17%	-89.85%

05-08	Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-11	US Equity Markets Close Mixed After March Producer Price Inflation Data	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
US Equity Markets Close Mixed After March Producer Price Inflation Data	04-11	MT
Top Midday Decliners	04-11	MT
Top Premarket Decliners	04-11	MT
Aptevo Therapeutics Inc. Provides Pipeline Update	04-10	CI
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4	03-07	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML	23-07-18	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-30	CI
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial	23-02-13	CI
Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors	23-01-09	CI
Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate in Venetoclax Treatment Naïve AML Patients	22-12-12	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics	22-11-09	CI
Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND	22-09-19	CI
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia	22-06-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Highlights

Filters